Endocrine Society's 13th Annual “Type 1 Diabetes Fellows Series”
Availability
On-Demand
13 Courses
Release on Nov 17, 2026 12:00 AM Central Standard Time
Expires on Dec 31, 2027
Cost
$0.00
Credit Offered
1 Participation Credit
  • Course Description
  • Learning Objectives
  • Faculty and Disclosures
  • Target Audience
  • Recommended

Type 1 diabetes (T1D) is a lifelong and often complex condition that affects an estimated 1.6 million people in the United States alone. People with T1D face a higher risk than the general population of severe hypoglycemia, diabetic ketoacidosis, vascular complications and reduced quality of life. T1D management is changing quickly. New medications and technologies often lead to updated care guidelines, so every healthcare provider who cares for people with T1D needs current, evidence-based education. That includes accurate diagnosis, clear patient-provider communication, the latest treatment recommendations and emerging research.

The Endocrine Society is making the on-demand materials from its 13th Annual Endocrine Fellows Series: Type 1 Diabetes Care and Management available to all healthcare providers through open access. The content was developed for endocrinology fellows by leading endocrinology faculty and draws on the Society's broad membership and long commitment to medical education. It covers the most up-to-date information on T1D care. Fellows, practicing endocrinologists, primary care clinicians, diabetes educators and other members of the care team can use these resources as a refresher or to catch up on recent advances, so they can give skilled, compassionate care to patients with T1D.

Upon successful completion these educational initiatives, participants should be better able to:
  • Discuss the progression of type 1 diabetes to recognize signs and support early diagnosis.
  • Discuss prevalence of type 1 diabetes at each stage, and also prevalence of overweight or obesity in this population.
  • Devise individualized treatment strategies that use new and emerging insulin and non-insulin therapies to manage individuals with type 1 diabetes with and without common comorbid conditions.
  • Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with type 1 diabetes and evaluate data from those technologies.
  • Recognize and evaluate individuals with type 1 diabetes for signs of depression and distress using updated guidelines and practice tools.
  • Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve care, long-term outcomes, exercise prescription, and sick day and hypoglycemia management of individuals with type 1 diabetes.
  • Describe current and emerging therapy for the treatment of pre-clinical type 1 diabetes

Rodolfo Galindo, MD - Program Co-Chair
University of Miami

Laya Ekhlaspour, MD – Program Co-Chair
University of California, San Francisco

Janet B. McGill, MD 
Washington University School of Medicine

Faisal Malik, MD, MSHS
Seattle Children’s Hospital 

Viral Shah, MD
Indiana University School of Medicine

Laura Nally
Yale School of Medicine

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES
University of Chicago 

Francisco Javier Pasquel, MD, MPH
Emory School of Medicine

Irl B. Hirsch, MD, MACP
University of Washington School of Medicine

Persis Commissariat, PhD, CDCES
Harvard Medical School

Camille E. Powe, MD
Harvard Medical School

Elizabeth R. Seaquist, MD
University of Minnesota Medical School

Robert Eckel, MD
University of Colorado Anschutz Medical Campus

Mark A. Atkinson, PhD
University of Florida, Departments of Pathology and Pediatrics 

Lorena Alarcon-Casas Wright, MD, FACE
University of Washington School of Medicine

Marconi Abreu, MD
University of Texas, Southwestern

Anne Peters, MD
University of Southern California

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Rodolfo J. Galindo, MD was supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). He has received research grants and support from Novo Nordisk, Boehringer, Roche, and Twiist/DEKA, and serves as an advisor for Amgen, Bayer, Boehringer, Dexcom, Gan&Lee, Eli Lilly, Novo Nordisk and Medtronic. Additionally, he is on the Board of Directors for the American Association of Clinical Endocrinology (AACE).

Laya Ekhlaspour, MD receives salary support from NIDDK. She has served on the Advisory Board of Abbot t, Diabetes Center Berne, Sequel, and Medtronic; and has consulted for Jaeb, and Tandem Diabetes Care; and has received honorarium from Medtronic, Tandem Diabetes Care, and Insulet.

Janet B. McGill, MD, MA, FACE has served as a consultant for Abbott, Bayer, Mannkind, Novo Nordisk, Pfizer, Vertex; and received grant funding from Cour, Diamyd, Lilly, Novo Nordisk, Viking. 

Lorena Alarcon-Casas Wright, MD, FACE serves on the Advisory Board for Genentech.

Anne Peters, MD serves on the Advisory Board for Medscape and Vertex, and receives research support from Insulet, Abbott Diabetes Care, and Zucara.

Camille E. Powe, MD serves as consultant for Mediflix, Inc; is a Pregnancy and Reproductive Health Interest Group Chair and Associate Editor for the American Diabetes Association; a journal section editor for Current Diabetes Reports; and receives grants from NIH/NIDDK, NIH/NICHD, K23, U01 and R01. Additionally, she receives research support from Dexcom.

Elizabeth R. Seaquist, MD has served on the Eli Lilly Global Diabetes Care Advisory Board, the NIDDK Advisory Committee and the External Advisory Committee for the University of Michigan Caswell Diabetes Center; has been a consultant for Zucara Therapeutics; is a member of the International Hypoglycemia Study Group; and received grants from the NIH and JDRF. 

Robert Eckel, MD has served as a Scientific Advisor for Regeneron Pharmaceuticals, Novo Nordisk, and Amgen; and has served on the Advisory Boards for 89bio, Ionis, Precision BioSciences and UpToDate.

Irl B. Hirsch, MD has served as a consultant for Abbot Diabetes Care, Roche and Hagar. He additionally receives research support from Sequel Med Tech and Cour Pharma.

Mark Atkinson, PhD  has served as a board member for Diamyd Medical; and has been a medical advisor for Quell Rx, Sanofi, Provention Bio, Endsulin, Vertex Pharmaceuticals and Novo Nordisk

Viral Shah, MD has received research grants from Dexcom, Eli Lilly, Enable Bioscience, Zucara Therapeutics, DEKA research, Medtronic, Breakthrough T1D and the NIH. Additionally, he serves as a consultant for Dexcom, Abbott, Insulet, Tandem Diabetes Care, Medtronic, Ascensia Diabetes Care, Embecta, Eli Lilly, Sanofi, NovoNordisk, Sequel Med Tech, Biomea Fusion, Roche, and T1D Scout.

The following faculty reported no relevant financial relationships: Faisal S. Malik, MD, MSHS; Persis Commissariat, PhD, CDCES; Marconi Abreu, MD

ACKNOWLDEGEMENT OF COMMERCIAL SUPPORT
Thank you to our supporters, Medtronic, Dexcom, Insulet, Abbott, Vertex, Xeris, and Breakthrough T1D for providing educational grants for the Type 1 Diabetes Fellows Program. 

 

While this content was originally developed for endocrinology fellows, but endocrinologists, physician associates, nurse practitioners, and allied healthcare professionals who specialize in the management of diabetes and diabetes related complications may benefit from this material.
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By